Logo image of HBC.OL

HOFSETH BIOCARE ASA (HBC.OL) Stock Fundamental Analysis

Europe - OSL:HBC - NO0010598683 - Common Stock

2.06 NOK
-0.01 (-0.48%)
Last: 10/24/2025, 7:00:00 PM
Fundamental Rating

1

Overall HBC gets a fundamental rating of 1 out of 10. We evaluated HBC against 73 industry peers in the Biotechnology industry. HBC may be in some trouble as it scores bad on both profitability and health. HBC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HBC has reported negative net income.
In the past year HBC has reported a negative cash flow from operations.
HBC had negative earnings in each of the past 5 years.
HBC had negative operating cash flow in 4 of the past 5 years.
HBC.OL Yearly Net Income VS EBIT VS OCF VS FCFHBC.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

With a Return On Assets value of -35.39%, HBC perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
The Return On Equity of HBC (-13486.42%) is worse than 71.43% of its industry peers.
Industry RankSector Rank
ROA -35.39%
ROE -13486.42%
ROIC N/A
ROA(3y)-32.56%
ROA(5y)-30.06%
ROE(3y)-185.37%
ROE(5y)-136.87%
ROIC(3y)N/A
ROIC(5y)N/A
HBC.OL Yearly ROA, ROE, ROICHBC.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

HBC has a Gross Margin (35.99%) which is in line with its industry peers.
HBC's Gross Margin has improved in the last couple of years.
HBC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y128.49%
GM growth 5Y94.79%
HBC.OL Yearly Profit, Operating, Gross MarginsHBC.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

0

2. Health

2.1 Basic Checks

HBC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HBC has been increased compared to 1 year ago.
HBC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for HBC is higher compared to a year ago.
HBC.OL Yearly Shares OutstandingHBC.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
HBC.OL Yearly Total Debt VS Total AssetsHBC.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 0.96, we must say that HBC is in the distress zone and has some risk of bankruptcy.
HBC's Altman-Z score of 0.96 is in line compared to the rest of the industry. HBC outperforms 53.25% of its industry peers.
A Debt/Equity ratio of 203.13 is on the high side and indicates that HBC has dependencies on debt financing.
With a Debt to Equity ratio value of 203.13, HBC is not doing good in the industry: 71.43% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 203.13
Debt/FCF N/A
Altman-Z 0.96
ROIC/WACCN/A
WACC8.46%
HBC.OL Yearly LT Debt VS Equity VS FCFHBC.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 0.96 indicates that HBC may have some problems paying its short term obligations.
The Current ratio of HBC (0.96) is worse than 72.73% of its industry peers.
A Quick Ratio of 0.59 indicates that HBC may have some problems paying its short term obligations.
HBC's Quick ratio of 0.59 is on the low side compared to the rest of the industry. HBC is outperformed by 80.52% of its industry peers.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.59
HBC.OL Yearly Current Assets VS Current LiabilitesHBC.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

HBC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.45%.
Looking at the last year, HBC shows a quite strong growth in Revenue. The Revenue has grown by 18.16% in the last year.
The Revenue has been growing by 30.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-9.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.56%
Revenue 1Y (TTM)18.16%
Revenue growth 3Y43.22%
Revenue growth 5Y30.59%
Sales Q2Q%-5.2%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HBC.OL Yearly Revenue VS EstimatesHBC.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
HBC.OL Yearly EPS VS EstimatesHBC.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 0 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HBC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HBC.OL Price Earnings VS Forward Price EarningsHBC.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HBC.OL Per share dataHBC.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HBC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HOFSETH BIOCARE ASA

OSL:HBC (10/24/2025, 7:00:00 PM)

2.06

-0.01 (-0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners34.27%
Inst Owner ChangeN/A
Ins Owners0.64%
Ins Owner ChangeN/A
Market Cap813.86M
Revenue(TTM)262.17M
Net Income(TTM)-137022000
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.1
P/FCF N/A
P/OCF N/A
P/B 801.05
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0.66
BVpS0
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.39%
ROE -13486.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.99%
FCFM N/A
ROA(3y)-32.56%
ROA(5y)-30.06%
ROE(3y)-185.37%
ROE(5y)-136.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y128.49%
GM growth 5Y94.79%
F-Score4
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 203.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.15%
Cap/Sales 2.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.96
Quick Ratio 0.59
Altman-Z 0.96
F-Score4
WACC8.46%
ROIC/WACCN/A
Cap/Depr(3y)35.77%
Cap/Depr(5y)87.88%
Cap/Sales(3y)7.85%
Cap/Sales(5y)29.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.56%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)18.16%
Revenue growth 3Y43.22%
Revenue growth 5Y30.59%
Sales Q2Q%-5.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-647.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-438.44%
OCF growth 3YN/A
OCF growth 5YN/A

HOFSETH BIOCARE ASA / HBC.OL FAQ

Can you provide the ChartMill fundamental rating for HOFSETH BIOCARE ASA?

ChartMill assigns a fundamental rating of 1 / 10 to HBC.OL.


What is the valuation status of HOFSETH BIOCARE ASA (HBC.OL) stock?

ChartMill assigns a valuation rating of 0 / 10 to HOFSETH BIOCARE ASA (HBC.OL). This can be considered as Overvalued.


How profitable is HOFSETH BIOCARE ASA (HBC.OL) stock?

HOFSETH BIOCARE ASA (HBC.OL) has a profitability rating of 1 / 10.